SCHEMBL6217296

SCHEMBL6217296

NC(=O)C1=CCCN(OC(=O)C(F)(F)F)C1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
THRB P10828 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
BLM P54132 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
MEN1 O00255 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
ALOX15 P16050 1/20 0.30
SLC6A1 P30531 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6215737 0.77
SCHEMBL17243109 0.73 P2RX7 (0.39)
SCHEMBL14993197 0.71 LMNA (0.35) LMNACHRM2CHRM4CHRM5THRB
SCHEMBL350960 0.69
SCHEMBL27667493 0.68
SCHEMBL22612784 0.67
SCHEMBL20958678 0.66
SCHEMBL29139503 0.66
SCHEMBL6216656 0.66 NR1H2 (0.47) LMNATHRBMEN1KMT2A
SCHEMBL15355468 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1176146-B1 CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2005-06-08 EP disclosed
US-6894168-B2 Carbamoyl tetrahydropyridine derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-05-17 US disclosed
EP-1449843-A1 Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives Taisho Pharmaceutical Co. Ltd. (JP) 2004-08-25 EP disclosed
US-20030191122-A1 Carbamoyl tetrahydropyridine derivatives NAKAZATO ATSURO (JP) 2003-10-09 US disclosed
US-6600038-B1 Intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF. involving Corticotropin Releasing Factor (CRF), such as depression, anxiety, TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-07-29 US disclosed
CN-1350536-A Carbamoyl tetrahydropyridine derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 2002-05-22 CN disclosed
EP-1176146-A1 CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191122-A1 Carbamoyl tetrahydropyridine derivatives CNR1, CRHR1, CRH LMNA 4473/4885CHRM2 192/4885CHRM4 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.